Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers

posted in: News | 0

Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it has licensed LMB-100, a next-generation immunotoxin, from the Center for Cancer Research (CCR) at the NCI, part … Continued

FDA Signs Collaborative Agreement with Emulate, Inc. to Use Organs-on-Chips Technology as a Toxicology Testing Platform for Understanding How Products Affect Human Health and Safety

posted in: News | 0

Emulate, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Food and Drug Administration’s (FDA) Office of Foods and Veterinary Medicine. Under this multi-year CRADA, Emulate and FDA will collaborate to … Continued

Twist Bioscience Raises $33 Million

posted in: News | 0

Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it raised an additional $33 million. To date, Twist Bioscience has raised a total of $166 million. “It is an exciting time to be … Continued

Muse bio secures $23M Series B financing led by Venrock

posted in: News | 0

Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital … Continued

ARMO BioSciences’ Immunotherapy AM0010 Receives Orphan Designation in Europe for the Treatment of Pancreatic Cancer

posted in: News | 0

ARMO BioSciences, Inc., a clinical-stage immuno-oncology company, announced that the European Commission (EC) has granted the Company’s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) Orphan designation for the treatment of pancreatic cancer.  The EC’s approval follows a positive opinion in November … Continued